PUBLISHED IN THE OFFICIAL JOURNAL OF THE PATENT OFFICE DATED – 25/11/2011-PART I

Sr. Application No. Title of the Invention Date of Applicant No. Application 1. 3232/CHE/2011 An Animal Feed Supplement For 20/09/2011 Gundareddy Amareswara Bird Immunization By Organic Rao Supplements 2. 5844/DELNP/2010 Treatment And Prevention Of 17/08/2010 Viromed Co., Ltd Cardiac Conditions Using Two Or More Isoforms Of Hepatocyte Growth Factor 3. 5866/DELNP/2010 Solid Forms Of Ortataxel 18/08/2010 Indena S.P.A. 4. 2844/DEL/2010 Solid Acid Catalyst And Method 30/11/2010 Jiangsu Sinorgchem For Preparing And Using The Same Technology Co., Ltd 5. 5847/DELNP/2010 Protease Stabilized, Acylated 17/08/2010 Novo Nordisk A/S Insulin Analogues 6. 5848/DELNP/2010 New Brassica Ogura Restorer Lines 17/08/2010 Pioneer Hi-Bred With Shotened Raphanus Fragment International, Inc. (SRF) 7. 5850/DELNP/2010 Cross-Neutralizing Human 17/08/2010 Humab, Llc Monoclonal Antibodies To Sars-Co V And Methods Of Use Thereof 8. 5907/DELNP/2010 Substituted Piperidines As 19/08/2010 Novartis Ag Therapeutic Compounds 9. 6093/DELNP/2010 Modified Release Composition 27/08/2010 Eurodrug Laboratories B.V. Comprising Doxofylline 10. 6085/DELNP/2010 Oxadiazoanthracene Compounds 27/08/2010 Transtech Pharma, Inc. For The Treatment Of Diabetes 11. 6102/DELNP/2010 Polypeptides And Polynucleotides, 27/08/2010 Compugen Ltd And Uses Thereof As A Drug Target For Producing Drugs And Biologics 12. 6115/DELNP/2010 Substituted 4-Hydroxypyrimidine- 27/08/2010 Merck Sharp & Dohme 5-Carboxamides Corp. 13. 6128/DELNP/2010 Microna (Mirna) And Downstream 30/08/2010 Julius Maximilians- Targets For Diagnostic And Universitat Wurzburg Therapeutic Purposes 14. 6136/DELNP/2010 Proteins Ezrin, Serpin B5, 30/08/2010 Ludwig-Maximilians- Peroxiredoxin-2 And Heat Shock Universitat Protein Beta-1 As Autoantigens For Psoriasis Vulgaris And Poststreptococcal Diseases 15. 6140/DELNP/2010 Process For The Preparation Of 2- 30/08/2010 Novartis Ag Amino-2 [2-(4-C3-C21-Alkyl- Phenyl)Ethyl]Propane-1, 3-Diols

1 Gopakumar Nair Associates

16. 6090/DELNP/2010 Stabilized Angiopoietin-2 27/08/2010 Medimmune Limited Antibodies And Uses Thereof 17. 6161/DELNP/2010 Pesticides 31/08/2010 Dow Agrosciences LLC 18. 6174/DELNP/2010 Short Fatty Acid Tail Polymyxin 31/08/2010 Northern Antibiotics Oy Derivatives And Uses Thereof 19. 6156/DELNP/2010 Pharmaceutical Solutions, Process 31/08/2010 UCB Pharma, S.A. Of Preparation And Therapeutic Uses 20. 6202/DELNP/2010 Combined Use Of Cholestanol 01/09/2010 Otsuka Pharmaceutical Co., Derivative Ltd. 21. 6179/DELNP/2010 A Process For Preparing 31/08/2010 Huntsman International Polyisocyanates LLC. 22. 6249/DELNP/2010 Substituted Cyclopentanes Having 03/09/2010 Inc Prostaglandin Activity 23. 6252/DELNP/2010 Crystalline Forms And Two 03/09/2010 Novartis Ag Solvated Forms Of 4-Amino-5- Fluoro-3-[5-(4-Methylpiperazin- 1- Yl)-1h-Benzimidazol-2-Yl] Quinolin-2(1H)-One Lactic Acid Salts 24. 6217/DELNP/2010 Heterocyclic Inhibitors Of Stearoyl- 01/09/2010 Novartis Ag Coa Desaturase 25. 6218/DELNP/2010 Use Of Virus-Induced Gene 01/09/2010 Pioneer Hi-Bred Silencing (Vigs) To Down- International, Inc. Regulate Genes In Plants 26. 6276/DELNP/2010 Tricyclic Pyridine Derivatives, 06/09/2010 Boehringer Ingelheim Medicaments Containing Such International GMBH Compounds, Their Use And Process For Their Preparation 27. 6267/DELNP/2010 Novel Androgenic Gland Hormone 03/09/2010 Vib Vzw 28. 6294/DELNP/2010 Processes For The Preparation Of 06/09/2010 Arena Pharmaceuticals, Inc. Intermediates Related To The 5- HT2C Agonist (R)-8-Chloro-1- Methyl-2,3,4,5-Tetrahydro-1h-3- Benzazepine 29. 6295/DELNP/2010 Therapeutic Peptidomimetic 06/09/2010 Aileron Therapeutics Inc. Macrocycles 30. 6296/DELNP/2010 Bioconjugates Made From 06/09/2010 Glycovaxyn Ag Recombinant N-Glycosylated Proteins From Procaryotic Cells 31. 6300/DELNP/2010 Monoclonal Antibodies For Tumor 06/09/2010 Curetech Ltd. Treatment 32. 6302/DELNP/2010 Pharmaceutical Composition 06/09/2010 Takeda Pharmaceutical Company Limited 33. 6303/DELNP/2010 Filamentous Fungi With Inactivated 06/09/2010 Danisco Us Inc., Genecor Protease Genes For Altered Protein Division Production 34. 6305/DELNP/2010 Thermoplastic Starch Compounds 06/09/2010 Swiss Caps Rechte Und Lizenzen Ag

2 Gopakumar Nair Associates

35. 6297/DELNP/2010 Polymer Paclitaxel Conjugates And 06/09/2010 Nitto Denko Corporation Methods For Treating Cancer 36. 6298/DELNP/2010 Selected Antibodies Binding To 06/09/2010 Board Of Regents, The Anionic Phospholipids & University Of Texas System Aminophospholipids And Their Use In Treating Viral Infections And Cancer 37. 6310/DELNP/2010 Compound 07/09/2010 Sterix Limited 38. 6313/DELNP/2010 Azeotrope-Like Composition Of 07/09/2010 Arkema, Inc. 1,1,1-Trifluoro-3-Chloropropene And Methyl Acetate 39. 6314/DELNP/2010 Azeotrope-Like Composition Of 07/09/2010 Arkema, Inc. 1,1,1-Trifluoro-3-Chloropropene And Dimethoxymethane 40. 6318/DELNP/2010 Compositions And Methods For 07/09/2010 Inc. Drug Delivery 41. 6306/DELNP/2010 Medium Chain Dicarboxylic Acids, 06/09/2010 Nestec S.A. Their Derivates And Metabolic Disorders 42. 6309/DELNP/2010 Azeotrope-Like Composition Of 07/09/2010 Arkema, Inc. 1,1,1-Trifluoro-3-Chloropropene And Trans-1,2- Dichloroethylene 43. 6320/DELNP/2010 Disease Markers And Uses Thereof 07/09/2010 Medimmune, LLC 44. 6319/DELNP/2010 Anti-Ifnari Antibodies With 07/09/2010 Medimmune, LLC., Reduced FC Ligand Affinity 45. 6332/DELNP/2010 Process For Preparing An 07/09/2010 Euro-Celtique S.A. Oxycodone Hydrochloride Composition Having Less Than 25 PPM 14-Hydroxycodeinone 46. 6335/DELNP/2010 Use Of Sirna To Achieve Down 07/09/2010 Senesco Technologies, Inc. Regulation Of An Endogenous Gene In Combination With The Use Of A Sense Construct To Achieve Expression Of A Desired Polynucleotide 47. 6323/DELNP/2010 Quinoline Derivatives As AXL 07/09/2010 Max-Planck-Gesellschaft Kinase Inhibitors Zur Forderung Der Wissenschaften E.V. 48. 6935/DELNP/2010 Antigen-And-Drug Vehicle 01/10/2010 The University Of Comprising Synthetic Peptide, And Tokushima Mucosal Vaccine Using The Same 49. 6943/DELNP/2010 DPP-IV Inhibitor Combined With 01/10/2010 Boehringer Ingelheim A Further Antidiabetic Agent, International Gmbh Tablets Comprising Such Formulations, Their Use And Process For Their Preparation 50. 6985/DELNP/2010 Triazolopyridinone Derivatives For 01/10/2010 , Inc. Use As Stearoyl Coa Desaturase Inhibitors

3 Gopakumar Nair Associates

51. 6988/DELNP/2010 Methods Of Treatment Using Anti- 01/10/2010 Carolus Therapeutics, Inc. MIF Antibodies 52. 7057/DELNP/2010 Novel Sirna Compounds For 06/10/2010 Quark Pharmaceuticals, Inc. Inhibiting RTP801 53. 7063/DELNP/2010 Double-Stranded Lipid-Modified 06/10/2010 National Institute Of RNA Having High RNA Advanced Industrial Interference Effect Science And Technology 54. 6980/DELNP/2010 Process For Continuous 01/10/2010 Centre National De La Oligomerization Of Isocyanates Recherche Scientifique (C.N.R.S.) 55. 1170/MUMNP/2010 Personal Care Composition 03/06/2010 Hindustan Unilever Limited 56. 1171/MUMNP/2010 Personal Care Composition 03/06/2010 Hindustan Unilever Limited 57. 1176/MUMNP/2010 Self - Tanning Effects 03/06/2010 Hindustan Unilever Limited 58. 1903/MUMNP/2010 Hair Conditioning Composition 09/09/2010 Hindustan Unilever Limited 59. 1904/MUMNP/2010 Make-Up Removal Composition 09/09/2010 Hindustan Unilever Limited Which Provides Good Foam 60. 1905/MUMNP/2010 Modification Of Particulate- 09/09/2010 Hindustan Unilever Limited Stabilised Fluid-Fluid Interfaces 61. 1907/MUMNP/2010 Conditioning Shampoo 09/09/2010 Hindustan Unilever Limited Composition 62. 1427/MUMNP/2010 Granules 02/07/2010 Hindustan Unilever Limited 63. 1753/MUMNP/2010 Cationic Copolymers Formulated 18/08/2010 Hindustan Unilever Limited With Pigmented Cosmetic Compositions Exhibiting Radiance With Soft Focus 64. 102/CHENP/2006 Orally Dosed Pharmaceutical 09/01/2006 Novartis Ag Compositions Comprising A Delivery Agent In Micronized Form 65. 145/CHENP/2006 Use Of 2,2-Dimethyl-3-(2,4- 12/01/2006 Bayer Cropscience Dichlorophenyl)-2-Oxo-1- Aktiengesellschaft Oxaspiro[4.5]Dec-3-En-4-Yl Butanoate For Controlling Acarids 66. 17/CHE/2009 Novel Crystalline Form Of 05/01/2009 Shodhana Laboratories Citalopram Intermediate Limited 67. 17/CHENP/2006 Arylamine-Substituted 02/01/2006 F. Hoffmann-La Roche Ag Quinazolinone Compounds 68. 17/CHENP/2011 Mixtures Of Amines Having 04/01/2011 Basf Se Guanidine Derivatives_ 69. 177/CHENP/2009 Process For Pure Irbesartan 09/01/2009 M/S Hetero Drugs Limited 70. 189/CHENP/2011 Glycosylated GLP-1 Peptide 11/01/2011 Otsuka Chemical Co., Ltd. 71. 1899/CHENP/2009 Arylphenoxy Catalyst System For 06/04/2009 SK Innovation Co., Ltd Producing Ethylene Homopolymer Or Copolymers Of Ethylene And A-Olefins

4 Gopakumar Nair Associates

72. 2150/CHE/2009 Picrorhiza Kurroa Extract For 04/09/2009 Munisekhar Medasani Prevention, Elimination And Treatment Of RNA Viruses And Infection Or Diseases Caused By The Same In Humans, Animals And Biotech Industry 73. 2149/CHE/2009 Method Of Treatment Of 04/09/2009 Munisekhar Medasani Neurodegenerative Or Neuro- Muscular Degenerative Diseases And Therapeutic Agent To Treat The Same 74. 220/CHE/2009 Enzymatic Process For The 30/01/2009 Matrix Laboratories Ltd Preparation Of Eslicarbazepine Acetate 75. 224/CHE/2009 Composition From Sphaeranthus 02/02/2009 Gokaraju, Ganga Raju Indicus And Garcinia Mangostana For The Control Of Metabolic Syndrome 76. 2873/CHE/2008 Novel Citrate Salt Of Carbapenem 20/11/2008 Orchid Chemicals & Antibiotic Pharmaceuticals Ltd 77. 230/CHE/2009 A Process To Enhance Ethanol 02/02/2009 Richcore Life Sciences Pvt. Yield From Molasses Fermentation, Ltd By Addition Of Enzymes Which Convert Unfer Mentable Sugars Into Fermentable Sugars 78. 2653/CHE/2009 An Improved Process For The 03/11/2009 Group PTC EHF Preparation Of Posaconazole 79. 3075/CHE/2009 Process For Preparing Quetiapine 11/12/2009 Dr. Reddy™S Laboratories Limited 80. 3384/CHENP/2009 Engineered Anti-TSLP Antibody 15/06/2009 Schering Corporation 81. 3005/CHE/2008 Improved Process For Preparing 01/12/2008 Actavis Group PTC EHF Prasugrel 82. 529/CHENP/2011 Phenoxazine Polymer Compound 25/01/2011 Sumation Co., Ltd. And Light Emitting Element Using The Same 83. 531/CHENP/2011 Artificial Kidney Precursor And 25/01/2011 Otsuka Pharmaceutical Process For Production Thereof Factory, Inc. 84. 536/CHENP/2011 Active Targeting Polymer Micelle 25/01/2011 Nanocarrier Co., Ltd Encapsulating Drug, And Pharmaceutical Composition 85. 544/CHENP/2011 Pyrrolidin-3-Ylmethyl-Amine As 25/01/2011 F. Hoffmann-La Roche Ag Orexin Antagonists 86. 545/CHENP/2011 Blends Of Stabilizers For Aliphatic 25/01/2011 Basf Se Polyesters 87. 563/CHENP/2011 Pharmaceutical Composition 27/01/2011 Nitto Denko Corporation Containing Surface-Coated Microparticles

5 Gopakumar Nair Associates

88. 564/CHENP/2011 Compound Containing 1,3-Diene 27/01/2011 Sumitomo Chemical Structure And Method For Company, Limited Producing Same 89. 566/CHENP/2011 Dermal Delivery 27/01/2011 Anterios, Inc. 90. 578/CHENP/2011 Novel Cholest-4-En-3-One Oxime 27/01/2011 Trophos Derivatives, Pharmaceutical Compositions Containing Them, And Preparation Method 91. 580/CHENP/2011 Microneedle Device And Method 27/01/2011 Hisamitsu Pharmaceutical For Enhancing The Efficacy Of Co., Inc. Japanese Encephalitis Virus Antigen With The Microneedle Device 92. 565/CHENP/2011 A Therapeutic Agent For A Lower 27/01/2011 Tobishi Pharmaceutical Co., Urinary Disease And An Agent For Ltd. Improving A Lower Urinary Tract Sympton 93. 599/CHENP/2011 Process For Preparing Oxazoline- 28/01/2011 Intervet International B.V. Protected Aminodiol Compounds Useful As Intermediates To Florfenicol 94. 612/CHENP/2011 Antibody Complex, Method For 28/01/2011 Tokyo Metropolitan Detecting Antigen, And Method Organization For Medical For Producing Antibody Complex Research 95. 614/CHENP/2011 A Method For Isolating 28/01/2011 Qiagen North American Substantially Pure And Holdings, Inc. Underegraded RNA From A Test Sample Containing RNA 96. 7266/CHENP/2010 Methods For Radiolabelling 10/11/2010 The Australian National Macromolecules University 97. 7267/CHENP/2010 Methods For Radiolabelling 10/11/2010 The Australian National Synthetic Polymers University 98. 7435/CHENP/2009 Antibodies To Hpd-1 18/12/2009 N.V. Organon 99. 658/CHENP/2011 Method Of Diagnosis Of A 31/01/2011 Sanofi-Aventis Deutschland Predisposition To Develop Gmbh Thrombotic Disease And Its Uses 100. 645/CHENP/2011 Use Of Opioids Or Opioid 31/01/2011 Universitat Ulm Mimetics For The Treatment Of Resistant Cancer Patients 101. 1034/KOLNP/2011 Rabies Virus-Based Recombinant 09/03/2011 The Government Of The Immunocontraceptive United States Of America Compositions And As Represented By The Methods Of Use Secretary Of The Department 102. 1043/KOLNP/2011 Triazolopyridine Compounds As 10/03/2011 Array Biopharma Inc. Pim Kinase Inhibitors 103. 1063/KOLNP/2011 Atropisomers Of (Hydroxyalkyl) 11/03/2011 Exelixis, Inc Pyrrole Derivatives 104. 1207/KOLNP/2011 Methods For Treating Cns Disorder 21/03/2011 Richter Gedeon Nyrt

6 Gopakumar Nair Associates

105. 122/KOLNP/2011 Nucleoside Cyclicphosphates 10/01/2011 Pharmasset, Inc 106. 1232/KOLNP/2010 Methods For Treating 06/04/2010 Takeda Pharmaceuticals Gastrointestinal Disorders North America Independent Of The Intake Of Food 107. 1239/KOLNP/2011 Liquid Aqueous Crop Protection 23/03/2011 Basf Se Formulations 108. 1240/KOLNP/2011 Crystalline Complexes Of 23/03/2011 Basf Se Pendimethalin And Metazachlor 109. 1270/KOLNP/2011 Piperazine Compounds With 24/03/2011 Basf Se Herbicidal Effect 110. 1297/KOLNP/2011 Clostridial Neurotoxins With 25/03/2011 Merz Pharma Gmbh & Co. Altered Persistency Kgaa 111. 1334/KOLNP/2011 Complex Consisting Of 29/03/2011 Adocia Polysaccharide And An HPB 112. 1352/KOLNP/2011 Fused Pyrrolidino-Cyclopropane 30/03/2011 Merck Patent Gmbh Derivatives As Selective 11- Betahydroxysteroid Dehydrogenase Type 1 Inhibitors 113. 143/KOLNP/2011 Pharmaceutical Compositions 11/01/2011 Istituto Luso Farmaco Based On Kinin B2 Receptor D'italia S.P.A. Antagonists And Corticosteroids, And Their Use 114. 1465/KOLNP/2010 Therapeutic Gene-Switch 26/04/2010 Intrexon Corporation Constructs And Bioreactors For The Expression Of Biotherapeutic Molecules, And Uses Thereof 115. 1473/KOLNP/2010 Methods Of Treating Or Preventing 28/04/2010 Biotec Pharmacon Asa Inflammatory Diseases Of The Intestinal Tract 116. 1478/KOLNP/2010 Use Of The Sequence Encoding 28/04/2010 Universidad De Zaragoza The Carboxyl-Terminal Domain Of The Heavy Chain Of Tetanus Toxin As A Drug 117. 1479/K OLNP/2010 Quinolone Analogs And Methods 28/04/2010 Cylene Pharmaceuticals, Related Thereto Inc. 118. 1485/KOLNP/2010 Compositions And Methods For 28/04/2010 Verenium Corporation Making Androstenediones 119. 1490/KOLNP/2010 C-19 Steroids For Therapeutic Uses 28/04/2010 Procima Gmbh 120. 1501/KOLNP/2010 Product, Dispenser And Method Of 29/04/2010 Georgia-Pacific Consumer Dispensing Product Products LP 121. 1502/KOLNP/2010 Fungicidal Mixtures Ii 29/04/2010 Basf Se 122. 1505/KOLNP/2010 Pyrimidine Substituted Purine 29/04/2010 Sbio Pte Ltd Derivatives 123. 1521/KOLNP/2010 Vaginal Delivery System 30/04/2010 Bayer Schering Pharma Oy 124. 1522/KOLNP/2010 Dispiro 1,2,4-Trioxolane 30/04/2010 Medicines For Malaria Antimalarials Venture MMV 125. 1532/KOLNP/2010 Human Anti-Amyloid Antibodies, 30/04/2010 Centocor Ortho Biotech Inc Compositions, Methods And Uses

7 Gopakumar Nair Associates

126. 1589/KOLNP/2010 Meningococcal Vaccine 05/05/2010 Novartis Ag Formulations 127. 1592/KOLNP/2010 Tropane Compounds 05/05/2010 Exelixis, Inc. 128. 1593/KOLNP/2010 Transdermal Delivery System For 05/05/2010 Acrux Dds Pty Ltd Hormones And Steroids 129. 1595/KOLNP/2010 Inhibitors Of C-FMS Kinase 05/05/2010 Janssen Pharmaceutica N. V. 130. 1596/KOLNP/2010 Stabilized Pediatric Suspension Of 05/05/2010 Janssen Pharmaceutica N. Carisbamate V. 131. 1601/KOLNP/20 10 Repair And Regeneration Of Renal 05/05/2010 , Incorporated Tissue Using Hukman Umbilical Cord Tissue-Derived Cells 132. 1628/KOLNP/2010 Method For The Preparation Of 07/05/2010 Sanofi-Aventis Morphine Compounds 133. 1633/KOLNP/2010 Novel Compounds Of Reverse 07/05/2010 Choongwae Pharma Turn Mimetics And The Use Corporation Therof (3) 134. 1637/KOLNP/2010 Process For Preparing Aldehydes 07/05/2010 Oxea Deutschland Gmbh 135. 1639/KOLNP/2010 Cycloalkyloxy-And 07/05/2010 Janssen Pharmaceutica, N. Heterocycloalky-Loxypyridine V Compounds As Modulators Of The Histamine H3 Receptor 136. 1641/KOLNP/2010 N-(Pyrazole-3-Yl)-Benxamide 07/05/2010 Merck Patent Gmbh Derivatives As Glucokinase Activators 137. 1642/KOLNP/2010 Pyridine Derivatives Useful As 07/05/2010 Merck Patent Gmbh Glucokinase Activators 138. 1644/KOLNP/2010 Method Of Makinig Ketals And 07/05/2010 Segetis, Inc Acetals 139. 1645/KOLNP/2010 Polyketal Compounds, Synthesis 07/05/2010 Segetis, Inc And Applications 140. 1663/KOLNP/2010 Pharmaceutical Composition For 10/05/2010 Proyecto De Biomedicina Cancer Treatment Cima, S.L. 141. 1664/KOLNP/2010 Polymorphic Form Of Rotigotine 10/05/2010 UCB Pharma Gmbh 142. 1668/KOLNP/2010 Humanized Antibodies Against 10/05/2010 Teva Biopharmaceuticals TL1A USA, Inc. 143. 1673/KOLNP/2010 Cosmetic Method For Increasing 10/05/2010 Euroderm Gmbh The Pigmentation Of The Skin Using Melanocyte Precursor Cells 144. 1701/KOLNP/2010 4(-3-( -2-(Phenyl)Morpholino)-2- 12/05/2010 Oxopyrrolodin-1-Yl)-N-(Thiazol-2- Incorporated Yl) Benzenesulfonamide Derivatives And Related Compounds As Modulators Of Ion Channels For The Treatment Of Pain

8 Gopakumar Nair Associates

145. 1703/KOLNP/2010 Multitype HPV Peptide 12/05/2010 The Johns Hopkins Compositions And Methods For University Treatment Or Prevention Of Human Papillomavirus Infection 146. 1707/KOLNP/2010 Multitarget Compounds Active At 12/05/2010 Giuliani International A PPAR And Cannabinoid Limited Receptor 147. 1720/KOLNP/2010 Conducting Formulation 13/05/2010 Merck Patent Gmbh 148. 1724/KOLNP/2010 Carboxamide Sulfonamide And 13/05/2010 Rigel Pharmaceuticals, Inc Amine Compounds For Metabolic Disorders 149. 1731/KOLNP/2010 Compositions For The Treatment 13/05/2010 Aciex Therapeapeutica, Inc And Prevention Of Eyelid Swelling Comprising An Osmotically Active 150. 1743/KOLNP/2010 Room Temperature Stable Non- 14/05/2010 Ovokaitys, Todd F. Crystalline Aspirin 151. 1745/KOLNP/2010 Process For The Modification Of 14/05/2010 Ovokaitys, Todd F. The Solid State Of A Compound And Co-amorphous Compositions Produced With Same 152. 1759/KOLNP/2010 5-Cyanothienopyridines 14/05/2010 Merck Patent Gmbh 153. 1761/KOLNP/2010 Isoquinoline Modulators Of ATP- 14/05/2010 Vertex Pharmaceuticals Binding Cassette Transporters Incorporated 154. 1764/KOLNP/2010 Use Melanocortins To Treat Insulin 17/05/2010 Ipsen Pharma S.A.S Sensitivity 155. 1 765/KOLNP/2010 Compositions Intended To Increase 17/05/2010 Exquim S.A. Piglet Appetite 156. 1766/KOLNP/2010 (1h-Pyrazolo (3,4-B) Pyridine-4- 17/05/2010 Vertex Pharmaceuticals Yl)-Phenyle Or -Pyridin-2-Yle Incorporated Derivatives As Protein Kinase C- Theta 157. 1770/KOLNP/2010 Process For The Preparation Of 2h- 17/05/2010 Bial-Portela & Ca., S. A. Chromene-3-Carbamate Derivatives 158. 1773/KOLNP/2010 Use Of Oligonucleotides With 17/05/2010 Baltic Technology Modified Bases In Hybridization Development, Ltd. Of Nucleic Acids 159. 1777/KOLNP/2010 Tubulysins And Processes For 17/05/2010 Endocyte, Inc. Preparing 160. 1794/KOLNP/2010 Dioxoanthracene Sulphonate 18/05/2010 Laboratoire Medidom S.A. Derivatives

9 Gopakumar Nair Associates